The latter drug prototype include pioglitazone, which is a selective PPAR-γ agonist and improves insulin sensitivity by augmenting insulin signalling at insulin-target sites, and further by reducing lipotoxicity and proinflammatory adipocytokine, tumor necrosis factor-ά (TNF-ά), promote insulin action31.Lipotoxicity is one of the pivotal mechanism implicated in mediation of insulin resistance at insulin target sites as well as β-cell dysfunction. The gene discussed is PPARG; the disease is Insulin resistance.